theheart.org on Medscape, November 07, 2013 Treating Obesity: New Algorithm Do you know how to approach your obese patients with a treatment plan? Learn more with this new guidance provided by the ...

PF-07976016 is under development for the treatment of obesity. It is administered as oral solution and oral suspension. The drug candidate acts by targeting gastric inhibitory peptide (GIPR).

S-309309 is under clinical development by Shionogi and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication ...

A recent study led by Principal Investigator Michael Goran, Ph.D., and Rachel Schenker, MD, a Fellow in the Children's ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...